
table of contents
table of contents
- What is Cannabis Rescheduling? - Controlled Substances Act Basics
- The difference between the UN schedule changes and the US changes
- The process of policy change - from Biden to Trump
- Proven Effects and Evidence of Medical Cannabis
- Practical Impact of Schedule III Changes
- Improving access to CBD (cannabidiol) products
- Critical viewpoints and concerns
- Republican opposition
- Implications for Japan - Global cannabis policy trends
- [Important] Impact on Japanese tourists - Example: Travel to Hawaii and precautions regarding marijuana
- Future timeline and challenges
- Summary – The Significance of a Historical Turning Point
| Item | Numerical value |
|---|---|
| Number of registered medical cannabis patients | 600 million people |
| Medical cannabis program implementation | 40 states + DC |
| Number of doctors qualified to recommend medical cannabis | 30,000 |
What is Cannabis Rescheduling? - Controlled Substances Act Basics
Schedule Classification System Overview
America'sControlled Substances Act (CSA)is a federal law enacted in 1970 that regulates drugs by dividing them into five schedules (classifications) based on their potential for abuse and whether they have medical uses.DEA (Drug Enforcement Administration)withHHS (Department of Health and Human Services)It is managed by.
Federal Agency Description
DEA (Drug Enforcement Administration): A federal investigative agency in the United States responsible for drug control and enforcement of the Controlled Substances Act. It is the equivalent of Japan's Drug Enforcement Agency.
HHS (Department of Health and Human Services): A US federal government agency that oversees public health, medical care, and social welfare. It plays a role similar to that of Japan's Ministry of Health, Labor, and Welfare.
FDA (Food and Drug Administration): An agency under the HHS that reviews and approves the safety and effectiveness of food, drugs, and medical devices. It is equivalent to the Pharmaceuticals and Medical Devices Agency (PMDA) of the Ministry of Health, Labor, and Welfare in Japan.
| Schedule | Definition | Abuse potential | Medical Use | Notable examples |
|---|---|---|---|---|
| Schedule I | No medical use, high abuse potential | Extremely high | None (not federally certified) | heroin,LSD, ecstasy,Cannabis (current situation) |
| Schedule II | Medical uses, high abuse potential | high | recognized | Cocaine, morphine, fentanyl, methamphetamine |
| Schedule III | Medical use, moderate abuse potential | Moderate to low | recognized | Ketamine, Tylenol containing codeine, anabolic steroids,Cannabis (after changes) |
| Schedule IV | Medical use, low abuse potential | Low | recognized | Xanax, Valium, Ambien |
| Schedule V | Medical use, very low abuse potential | Extremely low | recognized | Cough syrup (contains small amounts of codeine) |
Important points
In American law"Schedule"This refers to a categorization of things according to the level of regulation. It originally came from the fact that drug names were listed in a "schedule" attached to the main text of the law.
Schedule I Designation Conflict
Cannabis has been around since 1970."No medical use, high abuse potential"However, there were serious contradictions in this classification:
- 40 states + Washington, D.C., have legal medical marijuana programsIt is used for medical purposes by over 600 million registered patients.
- 24 states legalize marijuana for personal use64% of the public supports legalizing marijuana (2025 Gallup Poll)
- The federal government itself filed for a patent in 1998 recognizing the medical use of cannabis.It was approved in 2003 (Patent No. 6630507)
- The F.D.A.Chronic pain, chemotherapy-induced nausea and vomiting, and loss of appetite related to medical conditionsIt has been scientifically proven that it can be used in
"Medical research has effectively been put under lock and key. Schedule I makes large-scale placebo-controlled trials incredibly difficult. Without that data, policymakers are left making decisions in the dark."
Ryan Vandrey, PhD
Professor, Johns Hopkins University Institute for Cannabis Science
The difference between the UN schedule changes and the US changes
Points that are easily confused
Many of you may remember the news that the United Nations rescheduled cannabis five years ago in December 2020. However,The changes in the UN and the US are completely different systems and lawsThe scope of impact and content of the regulations are significantly different. Confusing these two will prevent a proper understanding of the significance of President Trump's decision.
The two "schedules" are completely different.
It can be confusing because the same word "schedule" is used.UN treaties and US domestic law are completely separate legal systemsLet's have a clear understanding of the differences between them in the table below.
| Comparison item | United Nations (December 2020) | America (December 2025) |
|---|---|---|
| Legal basis | 1961 Single Convention on Narcotic Drugs international treaties | Controlled Substances Act (CSA) U.S. Federal Law |
| decision-making body | United Nations Commission on Narcotic Drugs (CND) Voted by 53 countries | DEA (Drug Enforcement Administration) and HHS (Department of Health and Human Services) US Federal Government Decision |
| Changes | Removed from Schedule IV (However, it remains in Schedule I.) | Moved from Schedule I to Schedule III |
| What the changes mean | Marijuana not considered a "particularly dangerous drug" (Not on the same level as heroin) | Cannabis hasHas medical usesThe federal government recognized this for the first time |
| Substantial regulatory changes | Almost none It remains in Schedule I, so strict regulations remain in place. | Extremely large Lifting the ban on research, abolishing the 280E tax system, and improving banking access |
| Scope of application | Symbolic changes in international law It does not directly affect the domestic laws of each country. | Immediate legal effect in the United States |
| Voting result | Passed by a narrow margin 27 in favor, 25 against, 1 abstention | No votes Administrative procedures by presidential decree |
| Impact on Japan | Japan isDown votecast No impact on domestic law | No direct impact However, it will have a major impact as a global policy shift. |
Details of UN changes (2020)
August 2020, 12,United Nations Commission on Narcotic Drugs (CND)Based on the recommendations of the World Health Organization (WHO),Removal of cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic DrugsIt was decided to do so.
UN Treaty Schedule Structure (Different from the US)
| Schedule | Definition | Examples of applicable substances |
|---|---|---|
| Schedule I | The most dangerous drug For medical and scientific purposes only | Cocaine, fentanyl, heroin, and marijuana (continuing in 2020 and beyond) |
| Schedule IV | In Schedule I"Particularly dangerous"Drugs Drugs with "little therapeutic benefit" | heroin |
Practical impact of UN changes limited
The UN decisionSymbolically importantHowever, there was little real deregulation.
- Cannabis remains Schedule Iand is under strict international control.
- It does not directly affect the domestic laws of each country. - The treaty does not require countries to change their domestic laws
"While the UN committee's vote marks a softening of the stance on cannabis, it does not affect how it is regulated under international law, as cannabis remains in Schedule I. It has no practical impact on the drug's placement in Schedule IV, meaning the treaty does not oblige member states to impose additional controls on Schedule IV drugs beyond those imposed on Schedule I drugs."
Professor Robert Mavro
Vanderbilt University Law School Drug Law Specialist
Japan's opinion opposed in UN vote
The Japanese government voted against the UN's decision to remove cannabis from Schedule IV, and the Japanese representative explained the reasons for this. The government must have been aware of the problem at the time, but five years have passed and the situation has not improved. The expansion was foreseeable.Changing social perceptions of cannabisThe government will be held strictly accountable for not taking sufficient preparations or measures in response to this.
"Non-medical use of cannabis can have negative health and social consequences, particularly among young people."
Statement by the Representative of the Government of Japan at the United Nations Commission on Narcotic Drugs (December 2, 2020)
Details of America's Changes (2025)
In contrast, President TrumpSchedule changes in US domestic lawIt is,Dramatic changes with real and immediate legal effect.
Practical changes brought about by US schedule changes
| Field | Schedule I (before change) | Schedule III (revised) |
|---|---|---|
| Medical Use Certification | Federal definition of "no medical use" | Federal government officially recognizes it as having medical uses |
| Research | Extremely difficult Requires special licensing and rigorous screening | Much easier Large-scale clinical trials now possible |
| Tax system (280E) | Regular expenses cannot be deducted Effective tax rate: 70-80% | Regular expenses can be deducted Effective tax rate: 21-35% |
| Banking Services | Many banks refused to do business with them Cash-based business operations | Possible improvements (Additional legislation is needed for a complete solution) |
| Institutional Investors | Difficult to enter "Equivalent to heroin" explanation needed | Barriers to entry are significantly lowered |
| Social stigma | "No Medical Use" Label | Federally approved for medical use |
Why you shouldn't confuse the two changes
Confusing UN changes with American changes leads to the following misunderstandings:
- "The UN has already relaxed cannabis laws, so why is the US doing it now?"
This is a misunderstanding. The UN change was symbolic and had no effect on US domestic law. The US change is an independent decision that has real legal effect in the US. - "Now that it has been recognized by the United Nations, Japan must also change."
→ This is a misunderstanding. The UN decision does not obligate countries to change their domestic laws. Japan voted against the resolution, so it is not obligated to change its domestic laws. - "Changes in America won't affect the world"
→ This is partially a misunderstanding. The change in the US is directly a change in domestic law, but by lifting the ban on research in the world's largest pharmaceutical market,Indirectly, it will have a major impact on cannabis research and policy around the world.Give.
Summary: The essential differences between the two changes
| UN Changes (2020) | "Marijuana is not as dangerous as heroin"Iconic Certification Virtually no deregulation |
| Change in America (2025) | "Cannabis has medical uses"Substantive legal changes Immediate and huge impact on research, taxation, finance and industry |
The process of policy change - from Biden to Trump
| season | Event |
|---|---|
| June 2022 | President Joe Biden directs HHS and DEA to reschedule marijuana |
| June 2023 | Based on scientific and medical evaluation, HHSCannabis should be moved to Schedule IIIThis was recommended to the DEA.First federal government to officially recognize medical use of cannabis |
| June 2024 | The Department of Justice's Office of Legal Counsel issued an opinion stating that HHS's scientific and medical findings are binding on the DEA and should be given significant deference. |
| June 2024 | DEA proposes rule to move cannabis to Schedule III.Over 42,000 public commentsare received |
| June 2025 | A scheduled hearing before an administrative law judge was postponed. The rulemaking process was temporarily put on hold following President Trump's inauguration. |
| December 18, 2025 | President Trump signs executive orderand directed Attorney General Pamela Bondi to complete the rulemaking process "in the most expeditious manner." |
"President Trump first supported the reclassification of cannabis in September 2024, stating his desire to elucidate its medical uses through more research. Now he's making that happen. The changes underway are smart policy, backed by science, and overwhelmingly popular."
Saphira Galoob
Cannabis Policy Analyst
Proven Effects and Evidence of Medical Cannabis
FDA-approved medical benefits
Food and Drug Administration (FDA)conducted a comprehensive landscape review of the medical uses of cannabis and identified its use for the following medical conditions:Trusted scientific evidenceIt was concluded that there is.
| medical conditions | Evidence of effectiveness | Number of patients/statistics | Main reason for use |
|---|---|---|---|
| Chronic pain | Efficacy confirmed in multiple clinical studies | Affects approximately 25% of American adults (over 33% of older adults) | Medical cannabis users60 %used for pain management |
| Chemotherapy-induced nausea and vomiting | Clinically confirmed antiemetic effect | Experienced by approximately 70-80% of cancer patients | Alternative treatments when traditional antiemetics are ineffective |
| Loss of appetite related to a medical condition | Proven appetite-stimulating effect | Frequent occurrence in HIV/AIDS and cancer patients | Preventing weight loss and improving nutritional status |
Impact on seniors and veterans
| Item | Proportion |
|---|---|
| People aged 65 and over who have used cannabis in the past year | 10 out of 1 people |
| Elderly peopleCBDuse | 15 % |
President Trump at the signing ceremony"I've never had so many people begging me."He said, especiallyVeterans with service-related injuries,Elderly people with chronic illnesses that significantly reduce their quality of lifeHe revealed that there had been many requests from
Evidence suggests that some older adults who use medical cannabis:Improved health-related quality of life and pain controlHowever, among the elderly who use medical cannabis,Only just over 50% have discussed use with their healthcare providerThe lack of guidance on proper prescription and use is seen as a problem.
Practical Impact of Schedule III Changes
Dramatically reducing research barriers
Research into Schedule I substances required rigorous federal scrutiny and special licensing.Large-scale placebo-controlled clinical trialThis meant that it was virtually impossible to implement the measures.
"There are hundreds of cannabis products under the umbrella term 'cannabis,' all of which differ in very important and significantly different ways. There is a lack of data on therapeutic cannabis of the same quality as other medicines."
Dr. Ryan Vandley
Project leader, Johns Hopkins University, NIDA (National Institute on Drug Abuse) funded a five-year, $10 million research grant.
Research enabled by Schedule III
- Utilizing real-world evidence (real-world data): Evaluating health outcomes using data from real-world clinical settings
- Long-term health effects research in vulnerable populations: Understanding long-term health effects in adolescents and young adults
- Large-scale placebo-controlled trial: Accumulation of rigorous scientific evidence necessary for drug approval
- Product consistency and safety assessment: Quality control and consumer protection for various cannabinoid products
- Terpene and cannabinoid interaction researchJohns Hopkins University researchers discover that limonene alleviates the anxiety-inducing effects of THC.
Revolutionary Tax Changes - Repeal of Section 280E
Schedule changesThe most immediate and dramatic impactIt is,Internal Revenue Code Section 280EThis provision prohibits businesses that deal in Schedule I or II controlled substances from claiming tax deductions for ordinary business expenses.
What is Section 280E?
Internal Revenue Code Section 280Eis a tax law enacted in 1982 that states, "A business engaged in the trafficking of Schedule I or II controlled substances shall not be allowed any deduction for any amount paid or incurred during that business year." This law was designed to prevent drug traffickers from taking advantage of tax deductions, but it has also been applied to marijuana businesses operating legally under state law.
| Expense Items | When 280E is applied (Schedule I) | After the repeal of 280E (Schedule III) |
|---|---|---|
| Cost of Goods Sold (COGS) | Deductible | Deductible |
| Rent/rental fees | Non-deductible | Deductible |
| Salaries and labor costs | Non-deductible | Deductible |
| Marketing and advertising expenses | Non-deductible | Deductible |
| Insurance fee | Non-deductible | Deductible |
| Professional services fees (legal, accounting) | Non-deductible | Deductible |
| Effective tax rate | up to 70-80% | 21-35% (normal corporate tax rate) |
"Frankly, it's a testament to the resilience of the cannabis industry that it has been able to maintain a profitable model without the 280E tax credit. However, this change could immediately increase profits by approximately 30%."
Craig Small
Denver-Based Cannabis Lawyer
Economic impact of abolishing 280E
| Immediate profit margin improvement forecast | Total sales in Missouri alone from 2020 onwards (as of 2025) |
|---|---|
| 30 % | $45 billion |
"The Schedule I classification has alienated many institutional investors. It has been a tactic to harass shareholders about heroin,LSD, having to explain that you own a company that deals in a substance equivalent to cocaine... that's pretty tough."
Timothy Seymour
Founder and CIO of Seymour Asset Management, CNBC Contributor
Improving access to banking and financial services
The schedule change will allow cannabis businessesAccess to banking and financial servicesCurrently, many cannabis businesses face the following issues:
- Difficulty in opening a bank account (forced to operate business mainly on cash)
- Credit card payment networks cannot be used (Visa, Mastercard, etc. are prohibited)
- Limited access to regular business loans
- Unable to receive investment from institutional investors
However,The change to Schedule III alone will not completely solve these problems.Because cannabis remains a controlled substance and is not fully legalized at the federal level, additional legislative action is needed.
Improving access to CBD (cannabidiol) products
What is CBD - The Basics
CBD (cannabidiol)is a compound found in cannabis and hemp (industrial cannabis), and unlike THC (tetrahydrocannabinol),Does not produce psychoactive effects (the so-called "high" state)CBD has been reported to have effects such as anxiety reduction, anti-inflammatory, and pain relief, and is attracting attention worldwide.
| American Adults | Senior citizens |
|---|---|
| 20 % | 15 % |
Problems with current CBD regulations
Hemp-derived cannabinoid products(mainly containing CBD) is not a controlled substance under the Controlled Substances Act,Lack of a clear regulatory pathway by the FDAThis has led to the following problems:
- Lack of product consistency: Labels and actual ingredients often do not match
- Lack of consumer protection: Quality control standards are unclear
- The problem with synthetic cannabinoids: Synthetic cannabinoids such as Delta-8-THC, HHC, and THC-O are sold unregulated
- Legal Uncertainty for Full-Spectrum CBD ProductsLegality of products containing trace amounts of THC unclear
"Because hemp produces primarily CBD and small amounts of THC and other cannabinoids, manufacturers have no choice but to create their products synthetically. Claims that brands do not produce synthetic cannabinoid products and that they extract cannabis oil from excessive amounts of hemp biomass are simply not true."
Dr. Ryan Vandley
Johns Hopkins University conducts chemical analysis of commercially available hemp products
CBD Policy by Presidential Order
President Trump's executive order includes the following CBD-related directives:
| Instructions | Responsible agency | Objective |
|---|---|---|
| Working with Congress to Improve Access to Full-Spectrum CBD Products | White House Deputy Chief of Staff for Legislative, Political and Public Affairs | Providing access to appropriate full-spectrum CBD products while restricting the sale of products that pose serious health risks |
| Development of research methods utilizing real-world evidence | HHS (Department of Health and Human Services) | Improving Access to Hemp-Derived Cannabinoid Products and Developing Standards of Care |
| Consideration of Medicare Pilot Program | CMS (Centers for Medicare & Medicaid Services) | Increased access to CBD products for seniors (treating chronic pain, sleep disorders, and age-related symptoms) |
The Significance of the Medicare Pilot Program
Medicare is a public health insurance program in the United States that covers people over 65 and people with disabilities. If CBD products become eligible for reimbursement under Medicare,"The Holy Grail of Medicine"The move has the potential to attract institutional investors, including Timothy Seymour, but has also raised concerns from House Speaker Mike Johnson and FDA officials about costs, liability, and unprecedented steps to reimburse unapproved therapies.
Critical viewpoints and concerns
Not full legalization
The changes to Schedule III areIt does not mean federal legalization of cannabis.Cannabis remains a controlled substance and the following restrictions remain:
- Transporting and selling marijuana across state lines remains illegal
- Conflicts between federal and state law remain unresolved
- State-licensed cannabis businesses remain in violation of federal law
"Rescheduling cannabis is an incremental and imperfect improvement. Removing this drug from the shadow of Schedule I is a small step off the cliff of cruel prohibition, but it is not a lifeline for justice. Even with a reclassified schedule, the web of harmful criminal penalties remains intact, meaning the War on Drugs will continue to entangle Americans in a failed punishment system."
Andrew Birrell
President of the National Association of Criminal Defense Lawyers (NACDL)
New burdens from pharmaceutical regulatory transition
Schedule III substances are treated as medicines,Pharmaceutical-grade quality control and regulatory complianceThis raises the following concerns:
- Need for FDA approvalMany existing cannabis businesses lack the financial resources and expertise to obtain FDA approval.
- The entry of large pharmaceutical companies: Large pharmaceutical companies that can afford the huge costs of clinical trials may dominate the market.
- Selection of small businessesConcerns that existing cannabis growers and sellers without sufficient capital will be pushed out of the market
"Whether rescheduling happens next month or next year, the direction is clear: cannabis is moving toward pharmaceutical-grade standards. This change will require significant investments in infrastructure, quality systems, and regulatory readiness, potentially favoring larger operators and squeezing smaller businesses."
Alex Gonzalez
President and Co-Founder of Calyx Containers
Lack of scientific evidence regarding safety
The FDA is currentlyEpidiolexThe CBD-based medicine is approved only for the treatment of rare forms of epilepsy.High-quality clinical trials remain limited.
- Dramatic increase in THC levelsIn the 1970s, cannabis averaged 2% THC, but by 2025, products containing 35% or more THC will be common.
- Association with mental illnessStudies have shown that high levels of cannabis use are associated with psychosis and other serious mental health problems (over 10 hospitalizations for cannabis-related psychosis in 2017)
- Dependency IssuesCDC estimates that one in three cannabis users will develop addiction
Impact on the Transportation and Safety-Sensitive Industries
DOT-regulated employersThe Schedule III change is a major concern for the Department of Transportation. Currently, the DOT only requires drug testing for Schedule I and II substances, but if cannabis moves to Schedule III,DOT could lose legal authority to conduct marijuana testsThere is.
"Upon taking effect, the transition to Schedule III will immediately prohibit the ongoing testing of safety-sensitive transportation employees for cannabis use under 49 CFR Part 40 and HHS mandatory guidelines."
NTSB (National Transportation Safety Board) warning to DEA
Trucking industry experts and lawyers are calling for an express exception that would preserve the DOT's inspection authority.
- Legislative action by Congress: Legislation explicitly authorizing DOT cannabis testing of safety-sensitive workers
- Regulatory clarificationDOT, HHS, and Department of Justice jointly issue guidance allowing testing of Schedule III cannabis under 49 CFR Part 40
Republican opposition
Interestingly, before President Trump signed the executive order,20 Republican Senatorssigned a letter opposing the reclassification of marijuana, which also includes Senate Majority Whip John Barrasso of Wyoming and staunch Trump supporter Tommy Tuberville of Alabama.
"The only winners from this rescheduling are bad actors like Communist China, and Americans will pay the price."
Senator Ted Budd (North Carolina)
Leader of the opposition letter
This opposition shows that some conservatives still have concerns about deregulating marijuana.Poll shows 64% of Americans support marijuana legalizationIt appears that President Trump made the decision with public support in mind.

Implications for Japan - Global cannabis policy trends
Current situation in Japan
in Japan,Cannabis Control ActThe Cannabis Control Act will be revised in December 2023, and the possession, cultivation, and transfer of cannabis will be strictly regulated.New crime of "use" establishedOn the other hand,Conditional lifting of ban on cannabis-derived medicinesHowever, research into medical cannabis remains limited.
| Country / Region | Medical marijuana | Personal use cannabis | Policy Features |
|---|---|---|---|
| America | 40 states + DC | 24 states | Federally, Schedule III status; states have different policies |
| Canada | Nationwide | Nationwide (fully legalized in 2018) | First G7 country to fully legalize cannabis for personal use |
| Eur-lex.europa.eu eur-lex.europa.eu | legitimate | Legal (world's first in 2013) | First country in the world to legalize cannabis for personal use |
| Germany | legitimate | Partial legalization (2024) | Medical cannabis available by prescription in Europe's largest market |
| Netherlands | legitimate | Decriminalization (Coffee Shop System) | Contradiction: Selling it in coffee shops is allowed, but growing it is illegal |
| Israel | Legal (World-leading research center) | Illegal (partially decriminalized) | Leading the world in medical cannabis research |
| Japan | Conditional lifting of the ban on cannabis-derived medicines only (2023 amendment) | Illegal | New crime of use to be introduced in 2023, but research is extremely limited |
Challenges facing Japan
- Lack of scientific evidence: Cannabis research in Japan is extremely limited, making it difficult to build original evidence
- Social stigma: There is strong social prejudice against cannabis, and policy discussions tend to become emotional.
- Limited access to medical care: Patients with chronic pain and intractable epilepsy cannot access treatments available overseas.
- Risk of international isolationJapan's strict punitive approach may become outdated as major developed countries shift their policies to one based on scientific evidence
Future prospects
The US's Schedule IIIHarmonizing scientific evidence with policyThis shows an important principle. The following approach should be considered in Japan as well.
- Promoting medical cannabis research: Allowing clinical research under strict controls to build evidence for treatments suitable for Japanese patients
- Utilizing international research data: Utilizing large-scale research data accumulated in the United States, Canada, and other countries for policy decisions
- Patient-centered approach: Expanding treatment options for patients with intractable diseases and chronic pain
- Gradual policy change: Start with research and clinical application limited to medical use
[IMPORTANT] Impact on Japanese Tourists - Travel to Hawaii and Marijuana Precautions
Important points
"Now that marijuana is a Schedule III drug in the US, tourists can use it in Hawaii."That perception is completely wrong.
Changes in Federal Law and Hawaii State Law
By President TrumpSchedule III Changes at the Federal LevelWhen,Cannabis Legality Under Hawaii State LawIt is,A completely different legal systemLet's understand it clearly in the table below.
| Item | Federal Law (Schedule III) | Hawaii State Law (as of December 2025) |
|---|---|---|
| Legality of personal use cannabis | Still illegal Schedule III controlled substances | Illegal Purchase, possession, and use by tourists is a criminal offense |
| medical cannabis | Federally approved for medical use | Legal (since 2000) Hawaii 329 card required |
| Tourist access | Federal law does not directly regulate individual cannabis use | A temporary 329 card (valid for 60 days) is also required for medical purposes. Only medical marijuana cardholders from other states can apply. |
| Possession of 3 grams or less | Decriminalized, but with a $130 fine | |
| Use in public places | Completely illegal Banned on beaches, parks and hotel balconies |
The risks and rewards faced by Japanese tourists
Local legal risks in Hawaii
Consulate-General of Japan in Honoluluwarns that:
"In Hawaii, the law legalizing medical marijuana came into effect on December 28, 2000. In connection with this, there are reports that some marijuana dealers are selling marijuana to tourists, claiming that its use is now legal. It is important to be careful not to be fooled by the sellers' lies and sweet talk."
From the "Safety Information" of the Consulate-General of Japan in Honolulu
- fine: $130 fine for anything under 3 grams
- Criminal chargesPossession of 3 grams or more and involvement in sales are felonies
- Entry ban: Arrest history may make it difficult to enter the US in the future
- Deportation: Serious violations may result in deportation
Legal risks and rewards after returning to Japan
It came into effect in December 2023.Amended Cannabis Control ActTherefore, there was no explicit provision in the past.Punishment provisions regarding "use" (crimes of application)This has been clarified in the system. Following this amendment, attention is focused on whether Japanese citizens who use marijuana overseas, such as in Hawaii, will be punished upon their return to Japan.
Regarding this point, the government stated in the House of Representatives Health, Labor and Welfare Committee that"The use of drugs overseas cannot be prosecuted without evidence."This clearly shows the idea.
First, because the drug-related laws do not apply to the crime of drug use,Even if you smoke cannabis overseas, Japan's Narcotics and Psychotropic Substances Control Act does not apply.
House of Representatives Committee on Health, Labour and Welfare (November 10, 2023) Keizo Takemi, Minister of Health, Labour and Welfare
Furthermore, even after the revised bill created the crime of cannabis use,For people who smoke cannabis overseas and then return to Japan, if they are not in possession of cannabis, they will not be prosecuted even if cannabis metabolites are detected in their urine, unless they have recently traveled abroad and there is evidence to support their use in Japan.'
In other words, the official government position, expressed through Diet deliberations, is that even if someone uses marijuana under local law while in Hawaii, they will not be prosecuted in Japan simply because they "used it overseas."
| Status | Before December 2023 | After December 2023 (after system restructuring) |
|---|---|---|
| Legal cannabis use abroad | There was no crime of use, and there was no basis for punishment upon returning home. | Although the crime of use has been institutionalized, Cases cannot be brought against overseas use in countries where it is legal. |
| Bringing cannabis into Japan | felony Violation of the Cannabis Control Act and Customs Act | It is also a serious crime and is severely punished. |
During parliamentary deliberations,Criminal punishment is based on evidenceIt has been confirmed that this does not mean that actions taken overseas will be subject to unlimited penalties. The biggest risk for Japanese travelers is not whether they used it overseas, What will you bring back to Japan?This has not changed even after the amendment.
Prejudice against cannabis in Japanese society
"Cannabis possession and use is completely unacceptable in Japanese society. Many Japanese people consider cannabis to be an illegal drug on the same level as methamphetamine, heroin, and cocaine."
Ted Kubo
President and CEO of JTB Hawaii
"What really scares people is that innocent tourists who don't know the rules could accidentally bring something back to Japan and be arrested."
Mitsue Varley
Director of Hawaii Tourism Japan
Impact on the tourism industry
The Hawaii Legislature has been debating bills to legalize cannabis for personal use for the past few years (HB 1246, SB 1613, etc.).Decline in Japanese touristsThere were strong concerns about this, and the bill was not passed.
| Item | Details |
|---|---|
| Pre-pandemic | Japanese tourists are the largest number of foreign visitorsmajorityoccupied |
| As of 2025 | After the pandemic, the number of Japanese tourists has decreased due to inflation However, it remains an important market |
| Tourism industry concerns | Marijuana legalization could further reduce Japanese tourists |
| Hawaii's economic dependence | The economy is highly dependent on tourism, so the loss of the Japanese market would be a serious blow |
On the other hand, the potential market for cannabis tourism
Interestingly,Some Japanese tourists have alreadyHowever, there are also reports that people are visiting Hawaii for legal low-THC cannabis products, such as hemp-derived CBD products.
"Japanese tourists are coming all the way to Hawaii to use the cannabis products I sell. In that sense, Hawaii is a gold mine."
Waikiki CBD Shop Owner
From an interview with Hawaii Public Radio (October 2025)
Summary: US Federal Law Schedule III and its impact on Japanese tourists
Key conclusions
- Federal Schedule III legislation does not change Hawaii state law
- Hawaii law allows for medical use of cannabis
President Trump's decision to make it a Schedule IIIThis will have a significant impact on research, taxation, and industry, but will not change the legal situation regarding Japanese tourists traveling to Hawaii..
| Country / Region | Medical marijuana | Personal use cannabis | Policy Features |
|---|---|---|---|
| America | 40 states + DC | 24 states | Federally, Schedule III status; states have different policies |
| Canada | Nationwide | Nationwide (fully legalized in 2018) | First G7 country to fully legalize cannabis for personal use |
| Eur-lex.europa.eu eur-lex.europa.eu | legitimate | Legal (world's first in 2013) | First country in the world to legalize cannabis for personal use |
| Germany | legitimate | Partial legalization (2024) | Medical cannabis available by prescription in Europe's largest market |
| Netherlands | legitimate | Decriminalization (Coffee Shop System) | Contradiction: Selling it in coffee shops is allowed, but growing it is illegal |
| Israel | Legal (World-leading research center) | Illegal (partially decriminalized) | Leading the world in medical cannabis research |
| Japan | Conditional lifting of the ban on cannabis-derived medicines only (2023 amendment) | Illegal | New crime of use to be introduced in 2023, but research is extremely limited |
Future timeline and challenges
Outlook for the rulemaking process
President Trump's executive order does not "automatically" effect the schedule changes. The following process is required:
- Department of Justice (DOJ) and DEA Issue Final Rule: Formal rulemaking under 21 USC § 811
- HHS Review of Scientific and Medical Findings
- Federal Register NoticePublic comment period and opportunity for legal challenge
- Implementation TimelineThis process typically takes several months to over a year.
Many of the expertsThe rulemaking process will be completed in 2026However, it is possible that it could be delayed due to litigation or political opposition.
Remaining challenges
| Task | Current status | Measures required for resolution |
|---|---|---|
| Federal and state legal conflicts | State-Licensed Cannabis Businesses Still Violate Federal Law | Full legalization at the federal level or legislative measures that respect state laws |
| Access to banking services | Many financial institutions refuse to do business with cannabis | Legislative measures such as the SAFE Banking Act |
| commerce across state lines | Remains illegal | Building a regulatory framework at the federal level |
| Dealing with past criminal records | Records of millions of people convicted of cannabis-related crimes remain | Record expungement through legislation such as the MORE Act (Cannabis Opportunity Reinvestment Act) |
| Equity and Social Justice | Cannabis industry profits concentrated in large corporations, lack of reinvestment in communities | Strengthening social equity programs and supporting communities that have been disproportionately impacted in the past |
Summary – The Significance of a Historical Turning Point
President Trump's order to change cannabis to Schedule IIIA historic turning point in U.S. drug policy, the first in 55 yearsThis decision has the following important implications:
Five key points
- Scientific evidence wins: For the first time, the federal government officially recognizes medical use of cannabis, correcting 55 years of misclassification as having no medical use.
- Liberation of Research: The strict restrictions imposed by Schedule I designation have been lifted, allowing for large-scale clinical trials and research using real-world data.
- Economic reliefRepeal of Section 280E would dramatically reduce the tax burden on cannabis businesses and improve the sustainability of the industry.
- Improving patient accessPotential for better product quality and medical guidance for the more than 600 million medical cannabis patients and tens of millions of Americans who use CBD products
- Making policies a realityWith cannabis legal in 40 states and DC, the gap between federal policy and reality is finally narrowing.
But,Schedule III is not a perfect solutionThere are still many legal and practical challenges ahead before full federal legalization can be achieved. New problems could arise, such as the elimination of small businesses, market dominance by pharmaceutical companies, and a lack of scientific evidence regarding safety.
Nevertheless, this policy shift"Scientific Evidence vs. Ideology"This represents a step forward for science in addressing this fundamental conflict in drug policy. The large-scale research data being accumulated in the United States will likely influence drug policies around the world.
Countries including Japan should learn from the US policy shift.Cannabis policies that are appropriate for your country's cultural context and medical needsIt is time to examine these issues based on scientific evidence and build a drug policy that is fit for the 21st century, balancing patient access to treatment, public health, and social justice.
"This is a starting point, not an end point. But it is real progress: removing an unfair tax burden, reducing stigma, and opening the door to research, legitimacy, and long-term stability. Incremental change is how federal reform really happens."
Kyle Sherman
Founder and CEO of Flowhub, provider of technology to over 1,000 legal dispensaries across the US, and founding board member of the US Cannabis Roundtable (USCR)
References and Sources
- The White House. (2025). "Fact Sheet: President Donald J. Trump is Increasing Medical Marijuana and Cannabidiol Research"
- Johns Hopkins University Cannabis Science Laboratory, Ryan Vandrey, PhD
- Vicente LLP Cannabis Rescheduling Analysis (2025)
- National Association of Criminal Defense Lawyers (NACDL) Statement (2025)
- Cannabis Business Times Industry Analysis (2025)
- CNBC Financial Analysis (2025)
- PBS NewsHour Federal Policy Analysis (2025)
- American Institute of CPAs (AICPA) Tax Guidance (2024-2025)
- Moritz College of Law Drug Enforcement and Policy Center Timeline
- US Food and Drug Administration (FDA)
- US Department of Health and Human Services (HHS)
- US Drug Enforcement Administration (DEA)
- Photo by History in HD on Unsplash

![Mail-order product: MDMA × MM Analog [For Research Use]](https://www.thch-vape.shop/html/user_data/assets/img/products/213_250x250.webp)


